Company Legal Name
Latest Valuation
Founded Year
Headquarter
Colossal Biosciences Inc. is a biotechnology company pioneering advanced gene editing technologies to revive extinct species and conserve endangered wildlife. Based in Dallas, the company combines cutting-edge CRISPR gene editing, computational biology, and reproductive technologies to restore lost biodiversity. Colossal's groundbreaking approach positions it at the forefront of the emerging de-extinction field, targeting iconic species including the woolly mammoth, Tasmanian tiger, and dodo bird. The company's innovative platform addresses critical environmental challenges while creating potential commercial applications in conservation biology, synthetic biology, and pharmaceutical development. Colossal continues expanding its scientific capabilities and species portfolio to advance global conservation efforts.
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
